BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 2020;34:3149-60. [PMID: 32132655 DOI: 10.1038/s41375-020-0783-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Aru B, Pehlivanoğlu C, Dal Z, Dereli-Çalışkan NN, Gürlü E, Yanıkkaya-Demirel G. A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia. Front Immunol 2023;14:1108200. [PMID: 36742324 DOI: 10.3389/fimmu.2023.1108200] [Reference Citation Analysis]
2 Reschke A, Richards RM, Smith SM, Long AH, Marks LJ, Schultz L, Kamens JL, Aftandilian C, Davis KL, Gruber T, Sakamoto KM. Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1033993] [Reference Citation Analysis]
3 Lo Iudice G, De Bellis E, Savi A, Guarnera L, Massacci A, De Nicola F, Goeman F, Ottone T, Divona M, Pallocca M, Fanciulli M, Voso MT, Ciliberto G. Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD–positive acute myeloid leukemia. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03486-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Macaron W, Sargsyan Z, Short NJ. Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leukemia & Lymphoma 2022;63:1780-1791. [DOI: 10.1080/10428194.2022.2056178] [Reference Citation Analysis]
5 Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol 2022;97:885-94. [PMID: 35413152 DOI: 10.1002/ajh.26572] [Reference Citation Analysis]
6 Spring J, Munshi L. Hematology Emergencies in Adults With Critical Illness. Chest 2022;162:120-131. [DOI: 10.1016/j.chest.2022.02.004] [Reference Citation Analysis]
7 Jones SR, Rahrig A, Saraf AJ. Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience. Children 2022;9:503. [DOI: 10.3390/children9040503] [Reference Citation Analysis]
8 Fodil S, Arnaud M, Vaganay C, Puissant A, Lengline E, Mooney N, Itzykson R, Zafrani L. Endothelial cells: major players in acute myeloid leukaemia. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rinaldi I, Sutandyo N, Winston K. Comparison of early mortality between leukapheresis and non-leukapheresis in adult acute myeloid leukemia patients with hyperleukocytosis: a systematic review and meta-analysis. Hematology 2022;27:141-9. [DOI: 10.1080/16078454.2021.2024939] [Reference Citation Analysis]
10 Largeaud L, Bertoli S, Bérard E, Tavitian S, Picard M, Dufrechou S, Prade N, Vergez F, Rieu JB, Luquet I, Sarry A, Huguet F, Ruiz J, De Mas V, Delabesse E, Récher C. Genomic landscape of hyperleukocytic acute myeloid leukemia. Blood Cancer J 2022;12:4. [PMID: 34987148 DOI: 10.1038/s41408-021-00601-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Pimenta DB, Varela VA, Datoguia TS, Caraciolo VB, Lopes GH, Pereira WO. The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia. Front Cell Dev Biol 2021;9:764698. [PMID: 34869355 DOI: 10.3389/fcell.2021.764698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Bontinis A, Bontinis V, Koutsoumpelis A, Vasileios P, Georgia K, Giannopoulos A, Ktenidis K. Acute leukemia presenting as acute lower limb ischemia. Vasa 2021. [PMID: 34794339 DOI: 10.1024/0301-1526/a000977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Azoulay É, Soares M, Lengliné É. Preempting critical care services for patients with hematological malignancies. Intensive Care Med 2021;47:1140-3. [PMID: 34519846 DOI: 10.1007/s00134-021-06521-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Alahmari B, Alzahrani M, Al Shehry N, Tawfiq O, Alwasaidi T, Alhejazi A, Bakkar M, Al Behainy A, Radwi M, Alaskar A. Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation. JCO Glob Oncol 2021;7:1220-32. [PMID: 34343012 DOI: 10.1200/GO.20.00660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhang D, Zhu Y, Jin Y, Kaweme NM, Dong Y. Leukapheresis and Hyperleukocytosis, Past and Future. Int J Gen Med 2021;14:3457-67. [PMID: 34285568 DOI: 10.2147/IJGM.S321787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rinaldi I, Sari RM, Tedhy VU, Winston K. Leukapheresis Does Not Improve Early Survival Outcome of Acute Myeloid Leukemia with Leukostasis Patients - A Dual-Center Retrospective Cohort Study. J Blood Med 2021;12:623-33. [PMID: 34290537 DOI: 10.2147/JBM.S312140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Tu YQ, Fan Y, Zhu ZL, Chen J, Song TM, Zhang X, Lu Y, Wu DP. [Efficacy and safety of leukapheresis for hyperleukocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2021;42:161-4. [PMID: 33858049 DOI: 10.3760/cma.j.issn.0253-2727.2021.02.013] [Reference Citation Analysis]
18 Elbahlawan L, Galdo AM, Ribeiro RC. Pulmonary Manifestations of Hematologic and Oncologic Diseases in Children. Pediatr Clin North Am 2021;68:61-80. [PMID: 33228943 DOI: 10.1016/j.pcl.2020.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Göçer M, Kurtoğlu E. Effect of prophylactic leukapheresis on early mortality and overall survival in acute leukemia patients with hyperleukocytosis. Ther Apher Dial 2021;25:697-703. [PMID: 33686785 DOI: 10.1111/1744-9987.13645] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Lee H, Park S, Yoon JH, Cho BS, Kim HJ, Lee S, Kim DW, Chung NG, Cho B, Kim KB, Yoo J, Jekarl DW, Chae H, Lim J, Kim M, Oh EJ, Kim Y. The factors influencing clinical outcomes after leukapheresis in acute leukaemia. Sci Rep 2021;11:6426. [PMID: 33742034 DOI: 10.1038/s41598-021-85918-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhao J, Bewersdorf JP, Jaszczur S, Kowalski A, Perreault S, Schiffer M, Gore S, Podoltsev N, Prebet T, Shallis R, Zeidan AM. High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. Leuk Lymphoma 2021;62:1195-202. [PMID: 33325761 DOI: 10.1080/10428194.2020.1856835] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Spring J, Munshi L. Oncologic Emergencies: Traditional and Contemporary. Crit Care Clin 2021;37:85-103. [PMID: 33190777 DOI: 10.1016/j.ccc.2020.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
23 Bewersdorf JP, Zeidan AM. Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? Cells 2020;9:E2310. [PMID: 33080779 DOI: 10.3390/cells9102310] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
24 Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis. Transfusion 2020;60:2360-9. [DOI: 10.1111/trf.15994] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
25 Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Rev Hematol 2020;13:489-99. [PMID: 32248712 DOI: 10.1080/17474086.2020.1751609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
26 Shallis RM, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukhereje S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leuk Lymphoma 2020;61:1220-5. [PMID: 32100599 DOI: 10.1080/10428194.2020.1728753] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]